Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

Abstract excerpt

Core-binding factor acute myeloid leukemia (CBF-AML) has been associated with relatively better prognosis following intensive AML directed therapy, typically consisting of 7 days of continuous intravenous (IV) cytarabine and 3 days of anthracycline IV push (“7 + 3”), followed by multiple cycles of high-dose cytarabine consolidation [ 1 , 2 ]. However, such therapy has been associated with a 30–50% relapse rate [...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Retinoids in leukemia and cellular processes